Flamingo Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Flamingo Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $3.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Flamingo Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $3.3M Trade | TransData Nexus

Product Portfolio — Top 4 by Export Value

Flamingo Pharmaceuticals Limited exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Loperamide	Gastrointestinal	$1.4M	66	1.9%	6
2	Clotrimazole	Antifungals	$1.1M	21	1.1%	7
3	Gentamicin	Antibiotics	$800.0K	16	1.6%	5
4	Fosfomycin	Advanced Antibiotics	$57.2K	6	0.4%	8

Flamingo Pharmaceuticals Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $3.3M. The top category is Gastrointestinal (42.9% of portfolio), followed by Antifungals (31.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Flamingo Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Flamingo Pharmaceuticals Limited, established in 1985 as Flamingo Impex Pvt. Ltd. by Mr. Ashwin Thacker, is a Mumbai-based pharmaceutical company specializing in the manufacture and export of finished pharmaceutical formulations. The company is registered under the Corporate Identification Number (CIN) U51900MH1985PLC036572. As of March 31, 2023, Flamingo Pharmaceuticals reported an annual revenue of approximately $39.29 million USD and employed around 552 individuals. The company's website is www.flamingopharma.com.

2Manufacturing Facilities

Flamingo Pharmaceuticals operates two manufacturing facilities located in Rabale and Taloja, on the outskirts of Mumbai. The Rabale facility is dedicated to serving semi-regulated markets, while the Taloja facility focuses on contract manufacturing for regulated markets. Both facilities adhere to stringent international quality standards, including WHO-GMP, UK-MHRA, USFDA, and EU-GMP certifications.

3Key Leadership

The leadership team at Flamingo Pharmaceuticals includes:

Mr. Ashwin Jethalal Thacker: Founder and Director since June 23, 1986.

Mr. Sunil Kumar: Chief Executive Officer (CEO) since August 2, 2023.

Mr. Pranay Ashwin Thacker: Director since June 8, 2021.

Mr. Chhotulal Rawa Bhagwat: Director since October 25, 2022.

Ms. Meena Sanjiv Kapadi: Director since September 28, 2022.

These leaders guide Flamingo Pharmaceuticals in its mission to provide high-quality, affordable therapeutics globally.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Flamingo Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Flamingo Pharmaceuticals has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, and Australia. The company has obtained various regulatory approvals, such as WHO-GMP, UK-MHRA, USFDA, and EU-GMP certifications, ensuring compliance with international quality standards. Flamingo Pharma (UK) Ltd., a subsidiary of Flamingo Pharmaceuticals, was incorporated on April 23, 2014, in Harrow, Greater London, to strengthen its foothold in the UK market.

2Emerging Markets

Flamingo Pharmaceuticals has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, including WHO-GMP, facilitates its entry into these regions. Flamingo's products are available in over 50 countries across five continents, with a strong presence in Asia, Africa, Central America, and CIS countries.

3Geographic Strategy

Flamingo Pharmaceuticals demonstrates a diversified geographic strategy by operating in both regulated and semi-regulated markets. This approach mitigates concentration risk and allows the company to leverage opportunities across different regions. The establishment of Flamingo Pharma (UK) Ltd. and strategic partnerships in the US indicate a focused effort to strengthen its presence in regulated markets.

Flamingo Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Flamingo Pharmaceuticals has achieved FDA facility registrations and holds approved Abbreviated New Drug Applications (ANDAs) for its products. The company has also filed Drug Master Files (DMFs) with the FDA, ensuring compliance with regulatory requirements. Flamingo's manufacturing facilities are subject to FDA inspections, which have been conducted to verify adherence to Good Manufacturing Practices (GMP). The company's commitment to quality is reflected in its successful navigation of FDA regulatory processes.

2WHO & EU GMP

Flamingo Pharmaceuticals' manufacturing facilities are certified for compliance with WHO-GMP and EU-GMP standards. These certifications affirm the company's commitment to maintaining high-quality manufacturing processes that meet international standards. The adherence to WHO-GMP and EU-GMP guidelines enables Flamingo to supply products to various global markets, including the European Union and other regions that recognize these certifications.

3CDSCO & Indian Regulatory

Flamingo Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Flamingo Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not available, the company's adherence to international quality standards and its global presence position it as a significant competitor in both regulated and semi-regulated markets. Flamingo's focus on contract manufacturing and its diverse product portfolio further enhance its competitive standing.

2Key Differentiators

Flamingo Pharmaceuticals' key differentiators include its commitment to quality, as evidenced by certifications such as WHO-GMP, UK-MHRA, USFDA, and EU-GMP. The company's diversified product portfolio, encompassing over 500 formulations, and its strategic focus on both regulated and semi-regulated markets further distinguish it in the pharmaceutical industry.

3Strategic Position

Flamingo Pharmaceuticals' current strategic direction emphasizes expanding its presence in regulated markets through contract manufacturing and strategic partnerships. The establishment of Flamingo Pharma (UK) Ltd. and partnerships in the US reflect this focus. The company's future outlook includes leveraging its manufacturing capabilities and regulatory certifications to enhance its position in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating Flamingo Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Flamingo Pharmaceuticals has a track record of consistent export volume, with a total export value of $3.3 million USD across 109 shipments from 2022 to 2026. The company's portfolio concentration, with the top five products accounting for 100% of exports, indicates a focused approach to its product offerings. Flamingo's adherence to international quality standards and its global distribution network underscore its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Flamingo Pharmaceuticals as a supplier:

FDA Facility Registration: Confirm through the FDA's official database.

WHO-GMP Certification: Verify via the World Health Organization's official channels.

EU-GMP Certification: Check with the European Medicines Agency (EMA).

Frequently Asked Questions — Flamingo Pharmaceuticals Limited

How many pharmaceutical products does Flamingo Pharmaceuticals Limited export from India?

Flamingo Pharmaceuticals Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Loperamide ($1.4M), Clotrimazole ($1.1M), Gentamicin ($800.0K), Fosfomycin ($57.2K). Total export value is $3.3M.

What is Flamingo Pharmaceuticals Limited's total pharmaceutical export value?

Flamingo Pharmaceuticals Limited's total pharmaceutical export value is $3.3M, based on 109 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Flamingo Pharmaceuticals Limited cover?

Flamingo Pharmaceuticals Limited exports across 4 therapeutic categories. The largest are Gastrointestinal (42.9%, 1 products), Antifungals (31.4%, 1 products), Antibiotics (23.9%, 1 products).

Get Full Flamingo Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Flamingo Pharmaceuticals Limited

Flamingo Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Who is Flamingo Pharmaceuticals Limited? — Company Overview & Market Position

What Does Flamingo Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Flamingo Pharmaceuticals Limited Therapeutic Categories — 4 Specializations